Guardant Health reported Q1 2026 revenue of $301.7 million, up 48% year over year, and increased its full-year outlook to $1.30 billion–$1.32 billion. Company executives pointed to volume growth in oncology testing, including a 36% increase in oncology revenue and higher Guardant360 Liquid volumes. Management also emphasized pipeline-enabling upgrades, including planned whole-transcriptome RNA testing for Guardant360 Tissue. The firm said it has submitted data packages to CMS’s MolDx program across breast cancer surveillance and treatment monitoring settings, positioning reimbursement decisions as a near-term swing factor. The company’s results reinforce market appetite for liquid biopsy and MRD platforms that translate into both testing volume growth and incremental reimbursement pathways.